King Saud bin Abdulaziz University for Health Sciences (KSAU-HS) launched the 2nd Middle East Peritoneal Surface Oncology Group International (PSOGI) Conference in Jeddah on Sunday, February 9, 2025, in collaboration with the Ministry of National Guard Health Affairs (MNGHA) and Najran General Hospital. The three-day event brings together 71 specialized speakers from around the world to showcase the latest research and medical technologies in peritoneal surface oncology.
Context and Background
Peritoneal surface oncology focuses on cancers that spread to the peritoneum, the lining of the abdominal cavity, often originating from gastrointestinal or ovarian malignancies. The first PSOGI Middle East conference was held in 2023, establishing a regional platform for knowledge exchange. This second edition underscores Saudi Arabia’s growing role as a hub for specialized medical conferences, aligning with Vision 2030’s healthcare transformation goals to improve treatment outcomes and attract global expertise.
Key Details
Dr. Mohammad Alyami, chairman of the conference’s scientific committee, stated that the event aims to facilitate the exchange of expertise and discuss the latest developments with a select group of global experts. The conference features 71 speakers from various continents, including leading oncologists, surgeons, and researchers. Topics include advanced surgical techniques such as cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC), as well as emerging immunotherapy approaches.
Implications and Impact
The conference positions Saudi Arabia at the forefront of peritoneal surface oncology in the Middle East, fostering international collaboration that can accelerate clinical advancements. By hosting global experts, KSAU-HS and its partners strengthen the Kingdom’s reputation as a destination for medical innovation and education. This event also supports the training of Saudi healthcare professionals, enhancing local capacity to manage complex oncological cases.
Vision 2030 Alignment
The conference directly advances Vision 2030’s healthcare pillar, which prioritizes quality of life, preventive medicine, and access to world-class treatment. By promoting cutting-edge research and multidisciplinary collaboration, Saudi Arabia is building a sustainable healthcare ecosystem that reduces the need for patients to seek treatment abroad. Events like the PSOGI conference contribute to the Kingdom’s goal of becoming a leading medical tourism and research hub in the region.
20 Questions
Q1. What is the 2nd Middle East Peritoneal Surface Oncology Group International Conference?
A1. It is a scientific conference hosted by King Saud bin Abdulaziz University for Health Sciences in Jeddah, focusing on the latest research and treatments for peritoneal surface oncology, with 71 international experts.
Q2. When and where was the conference launched?
A2. The conference was launched on Sunday, February 9, 2025, in Jeddah, Saudi Arabia, and runs for three days.
Q3. Who organized the conference?
A3. The conference was organized by KSAU-HS in collaboration with the Ministry of National Guard Health Affairs and Najran General Hospital.
Q4. How many speakers participated in the conference?
A4. A total of 71 specialized speakers from various continents participated in the conference.
Q5. Who is Dr. Mohammad Alyami?
A5. Dr. Mohammad Alyami is the chairman of the conference’s scientific committee, responsible for overseeing the program and ensuring expert participation.
Q6. What is peritoneal surface oncology?
A6. Peritoneal surface oncology is a specialized field focusing on cancers that spread to the peritoneum, the lining of the abdominal cavity, often from gastrointestinal or ovarian cancers.
Q7. What is the main goal of the conference?
A7. The main goal is to facilitate the exchange of expertise and discuss the latest developments in peritoneal surface oncology among global experts.
Q8. How does the conference support Vision 2030?
A8. It supports Vision 2030 by enhancing healthcare quality, promoting medical research, and positioning Saudi Arabia as a hub for specialized medical conferences.
Q9. What are some topics discussed at the conference?
A9. Topics include cytoreductive surgery, hyperthermic intraperitoneal chemotherapy (HIPEC), immunotherapy, and other advanced treatment modalities.
Q10. Which organizations collaborated on this conference?
A10. The conference was a collaboration between KSAU-HS, the Ministry of National Guard Health Affairs, and Najran General Hospital.
Q11. Why is this conference important for Saudi healthcare?
A11. It brings international expertise to Saudi Arabia, enhances local medical training, and improves treatment options for complex cancers, reducing the need for overseas treatment.
Q12. What is the role of the Ministry of National Guard Health Affairs?
A12. The Ministry of National Guard Health Affairs co-organized the conference and supports its objectives of advancing oncology care and medical education.
Q13. How does the conference benefit international participants?
A13. International participants gain access to regional insights, collaborate with Saudi experts, and contribute to global knowledge exchange in peritoneal surface oncology.
Q14. What is the significance of Najran General Hospital’s involvement?
A14. Najran General Hospital’s involvement highlights the expansion of specialized oncology services beyond major cities, reflecting healthcare decentralization under Vision 2030.
Q15. How does the conference foster innovation?
A15. By showcasing the latest research and technologies, the conference stimulates innovation and encourages adoption of new treatment protocols in Saudi Arabia.
Q16. What is cytoreductive surgery?
A16. Cytoreductive surgery is a procedure to remove visible tumor deposits from the abdominal cavity, often combined with HIPEC for peritoneal cancers.
Q17. What is hyperthermic intraperitoneal chemotherapy (HIPEC)?
A17. HIPEC is a treatment where heated chemotherapy drugs are circulated in the abdominal cavity after surgery to kill remaining cancer cells.
Q18. How does Saudi Arabia’s healthcare transformation relate to this conference?
A18. The conference aligns with healthcare transformation by emphasizing specialized care, research, and international partnerships to improve patient outcomes.
Q19. Will there be future editions of this conference?
A19. Given the success of the first two editions, it is expected that the conference will continue as a regular event, reinforcing Saudi Arabia’s role in oncology leadership.
Q20. What is the expected impact on cancer treatment in Saudi Arabia?
A20. The conference is expected to accelerate adoption of advanced treatments, boost local expertise, and improve survival rates for peritoneal cancer patients in Saudi Arabia.
Reader Feedback
We value your thoughts. Please share your feedback on this article.
Your feedback helps us improve our coverage.